Effectiveness of Serum Leucine-rich Alpha-2 Glycoprotein Levels on IBD

S

Showa Inan General Hospital

Status

Enrolling

Conditions

LRG Levels

Treatments

Diagnostic Test: serum leucine-rich alpha-2 glycoprotein (LRG) levels

Study type

Observational

Funder types

Other

Identifiers

NCT04535882
LRG

Details and patient eligibility

About

We attempt to examine the association between serum leucine-rich alpha-2 glycoprotein (LRG) levels and endoscopic activity in patients with possible ulcerative colitis (UC) or Crohn's disease (CD) to determine whether LRG was a predicting marker for UC or CD.

Full description

Serum samples were collected from patients, and scores for clinical and endoscopic activity of disease were obtained by reviewing the clinical records of patients. Serum sampling and colonoscopy with histology were performed within 7 days.The disease activity of UC and CD patients was evaluated by the Mayo score and Crohn disease activity index (CDAI), respectively. The Mayo endoscopy score was evaluated. UC patients whose Mayo endoscopy score was 2 or 3 were divided into the active UC group. CD patients whose CDAI >150 were divided into the active CD group.

Enrollment

125 estimated patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients whom possible UC or Crohn disease was suspected

Exclusion criteria

other autoimmune diseases acute or chronic renal failure chronic heart diseases liver cirrhosis cancer acute or chronic infections ischemic colitis infectious colitis

Trial contacts and locations

1

Loading...

Central trial contact

Masashi Kajiyama, MD; Akira Horiuchi, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems